Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease
Open Access
- 16 September 2021
- journal article
- review article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 94 (5) , e13101
Abstract
The coronavirus disease‐19 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) challenged globally with its morbidity and mortality. A small percentage of affected patients (20%) progress into the second stage of the disease clinically presenting with severe or fatal involvement of lung, heart and vascular system, all contributing to multiple‐organ failure. The so‐called ‘cytokines storm’ is considered the pathogenic basis of severe disease and it is a target for treatment with corticosteroids, immunotherapies and intravenous immunoglobulin (IVIg). We provide an overview of the role of IVIg in the therapy of adult patients with COVID‐19 disease. After discussing the possible underlying mechanisms of IVIg immunomodulation in COVID‐19 disease, we review the studies in which IVIg was employed. Considering the latest evidence that show a link between new coronavirus and autoimmunity, we also discuss the use of IVIg in COVID‐19 and anti‐SARS‐CoV‐2 vaccination related autoimmune diseases and the post‐COVID‐19 syndrome. The benefit of high‐dose IVIg is evident in almost all studies with a rapid response, a reduction in mortality and improved pulmonary function in critically ill COVID‐19 patients. It seems that an early administration of IVIg is crucial for a successful outcome. Studies’ limitations are represented by the small number of patients, the lack of control groups in some and the heterogeneity of included patients. IVIg treatment can reduce the stay in ICU and the demand for mechanical ventilation, thus contributing to attenuate the burden of the disease.Keywords
This publication has 121 references indexed in Scilit:
- Intravenous Immunoglobulin Treatment in Humans Suppresses Dendritic Cell Function via Stimulation of IL-4 and IL-13 ProductionThe Journal of Immunology, 2014
- Intravenous immunoglobulin modulates the expansion and cytotoxicity of CD8+ T cellsImmunology, 2014
- Anti‐inflammatory effects of high‐dose IgG on TNF‐α‐activated human coronary artery endothelial cellsEuropean Journal of Immunology, 2012
- Long-Term Therapy with Intravenous Immunoglobulin is Beneficial in Patients with Autoimmune DiseasesClinical Reviews in Allergy & Immunology, 2011
- Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulinJournal of Allergy and Clinical Immunology, 2011
- Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspectiveCritical Care, 2011
- IVIg Attenuates TLR-9 Activation in B Cells from SLE PatientsJournal of Clinical Immunology, 2010
- Sialic acid–IVIg targeting CD22Blood, 2010
- Intravenous Immunoglobulin and CytokinesAnnals of the New York Academy of Sciences, 2007
- Intravenous Immunoglobulin: Adverse Effects and Safe AdministrationClinical Reviews in Allergy & Immunology, 2005